Life sciences companies face unique issues in accessing capital markets, including matters related to due diligence, public relations, regulatory and intellectual property. Goodwin offers a team of sophisticated life sciences lawyers who have expertise with these issues and extensive experience across the full breadth of equity and debt capital markets, advising issuers, sponsors, underwriters and investors in a variety of transactions to ensure deals close smoothly and in a timely way.
And we believe Goodwin has a unique position within BigLaw given our life sciences team’s collaboration with our robust private equity, technology and healthcare practices. With our largest and strongest practices working together, Goodwin is exceptionally suited to address whatever the future brings.
With over 150 lawyers focused on serving over 600 life sciences clients, our integrated, full service life sciences team offers deep transactional expertise drawing on firm resources spread across the globe. In the past five years Goodwin has completed over 95 IPOs for $41 billion in equity proceeds, and also worked on over 550 public offerings with over $135 billion in capital raised.